Modi asks pharma cos to focus on real research

December 15th, 2009|

“In this age of product-process patent and intellectual property rights, discovery of new drugs holds significance. Moreover, a social environment, under which the firms follow the rule at their own, should also be created. If this is not done, it will make way for the rise of holistic healthcare culture in India too,” said Gujarat’s Chief Minister Narendra Modi.

CRAMS factor

December 15th, 2009|

Piramal Healthcare, India's fourth-largest pharmaceutical company by revenue, has seen its contract research and manufacturing services (CRAMS) business fare badly in the past year or so. Going by the company's guidance, revenues from the segment, which accounted for about a quarter of its revenues in the first half of this fiscal, could decline through the full fiscal year.

Cipla in talks to supply drugs to Germanys BI

December 15th, 2009|

German drugmaker Boehringer Ingelheim (BI) has started discussions with Cipla for a drug supply agreement that could see the Indian company supply generic drugs to the $17-billion German company for two of its drugs, including one of its best sellers. The Indian company is also discussing similar deals with other global pharma majors, said two persons familiar with the matter.

GE Healthcare launches FTA DMPK cards for storage of study samples

December 15th, 2009|

GE Healthcare announced the launch of FTA DMPK cards for the collection and storage of blood samples for use in pharmacokinetic and toxicokinetic (PK/TK) studies.

Japan pharma market a preferred destination for Indian cos

December 14th, 2009|

With the Japanese government's move towards generics, Japanese pharmaceutical market seems to have become an attractive destination for India.

Pharms year of merger mania

December 14th, 2009|

Another year of change and consolidation in the pharma industry began with the announcement of two mega-mergers and a long-expected takeover – and ends with the fallout of those mergers beginning to bite.

Piramal Healthcare eyeing overseas acquisitions: Swati Piramal

December 10th, 2009|

Pharma major, Piramal Healthcare, is eyeing acquisitions overseas, a top company official said.

GSK to continue M&As in emerging markets

December 10th, 2009|

British drugmaker GlaxoSmithKline says it will pursue acquisitions in emerging markets, but expectations of family-owned companies are ‘unreasonable’ and the company would not pay such a price.

Aventis launches rural market division, eyes 2 per cent share in 5 yrs

December 10th, 2009|

French company Aventis Pharma on Thursday said it has launched a rural market division with 10 products and a sales team of 300 people as it eyes a bigger share of the fast growing Indian rural market, a top company official said.

Piramal to strengthen diagnostic services

December 9th, 2009|

Pharma giant Piramal Healthcare Limited plans to strengthen its diagnostic services. It will network its diagnostic centres to provide customers the flexibility of visiting any of these centres for getting the tests done.

Local firms must step up biologics play

December 9th, 2009|

Pure-play global biologics firms have long pleaded with the government for a tighter regulatory framework for approval of biosimilars in India. Companies like Amgen, Biogen and Genentech (now part of Roche) have some of the biggest successes in biological drugs and could be naturally worried about the way copied drugs are approved and sold in India.

Pharma firms to conduct H1N1 vaccine human trials in India

December 8th, 2009|

An indigenous swine flu vaccine is far from ready but India has given the green signal to two foreign pharmaceutical giants to begin human trials of their vaccine in the country.

Ranbaxy exits Nihon JV, sells out to partner

December 8th, 2009|

Ranbaxy Laboratories on Tuesday said it was selling its 50 per cent stake in its Japanese joint venture Nihon Pharmaceutical Industry (NPI) to its partner Nippon Chemiphar.

BUZZ IN PHARMA BIZ

December 6th, 2009|

On Friday, shares of Cipla touched a 52-week high of Rs 360.80 on the BSE following its management saying early this week that the company is in talks with ‘multiple global companies’ for a drug research and supply agreement. The company has neither confirmed nor denied that it is talking to Pfizer, the world’s largest drugmaker, for an alliance on this front.

Indian pharma world discovers Bharat

December 6th, 2009|

After decades of hunt for fortune abroad, India's pharmaceutical companies now plan to strike gold in their own backyard. Large players from Ranbaxy to Dr Reddy's and Piramal Healthcare are all headed to rural India to boost their revenues.

DISCOUNT PILLS

December 6th, 2009|

The $8 billion domestic pharmaceuticals market is facing drug price erosion. An aggressive lot of home-grown small and medium-sized pharmaceutical companies, namely, Shantha Biotechnics, Aurobindo Pharmaceuticals, Mankind Pharma and Natco Pharma, have resorted to drastic price cuts in their drug offerings in recent months. Left with no option, global pharmaceutical majors such as AstraZeneca, GlaxoSmithKline, Novartis, Pfizer and Roche, and domestic drug majors like Cipla, Lupin, Ranbaxy, Sun Pharmaceuticals are also cutting the prices of their own drugs.

India has ‘world-class health care’, say Canadians

December 3rd, 2009|

Canadians are increasingly looking to India for timely medical treatment as wait periods under the country's public health system get longer. Many are saying they would recommend India to anyone seeking "world-class health care" at a small cost.

Healthcare to become $77-bn sector in India by 2012: Report

December 3rd, 2009|

India's healthcare sector is expected to grow at 23 per cent annually to become a $77-billion industry by 2012, according to a recent report.

Aurobindo Pharma aims to treble revenue by 2014

November 20th, 2009|

The drug maker expects sales from the Pfizer alliance to contribute some 25% to its total sales in four years.

In healthcare, we can at best play catch-up with China

November 19th, 2009|

Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.